ReviewPharmaceutics2026
Bioactive Anti-Inflammatory Compounds and Therapeutic Strategies for Promoting Resolution.
Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Special Issue "Bioactive Compounds in the Prevention of Chronic Diseases".International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation plays a crucial role in defending the body against harmful stimuli and maintaining physiological balance; however, when it becomes chronic, it contributes to the pathogenesis of several long-term diseases, including autoimmune conditions, cardiovascular and neurodegenerative disorders, and various cancers. Although conventional anti-inflammatory drugs provide symptomatic relief, their long-term use is often associated with adverse side effects. This limitation has shifted scientific attention toward naturally occurring bioactive molecules with potent, safer anti-inflammatory activity. Dietary incorporation of phytopharmaceuticals, such as flavonoids, polyphenols, alkaloids, terpenoids, and fatty acids, has been shown to regulate immune and oxidative mechanisms and to modulate key inflammatory signaling cascades, including the NF-κB, mitogen-activated protein kinase (MAPK), and JAK/STAT pathways. These agents also influence cytokine secretion, NLRP3 inflammasome activation, and antioxidant defense mechanisms involving the Nrf2/HO-1 axis. The current review emphasizes the relevance of major natural plant products in therapy, like quercetin and rutin, resveratrol, glycyrrhizin, lycopene, and indole-3-carbinol. Moreover, recent progress in anti-inflammatory research has focused on novel resolution-based strategies that extend beyond inflammation and oxidative stress suppression. In addition, the review discusses innovations including nanoformulation-assisted targeted delivery, specialized pro-resolving lipid mediators such as resolvins and protectins, and microbiota-oriented therapeutic approaches. Additionally, the review highlights the integration of personalized medicine supported by multi-omics technologies to enhance treatment precision and clinical outcomes. By synthesizing findings from preclinical studies and clinical investigations, this work emphasizes the synergistic therapeutic potential of bioactive compounds from natural sources and resolution-enhancing techniques in restoring immune homeostasis and effectively mitigating chronic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.